Eli Lilly And Co (NYSE:LLY) Shares Bought by Hyman Charles D

Hyman Charles D raised its stake in Eli Lilly And Co (NYSE:LLY) by 1.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,575 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Hyman Charles D’s holdings in Eli Lilly And Co were worth $1,061,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of Eli Lilly And Co by 1.7% in the 1st quarter. FMR LLC now owns 13,916,001 shares of the company’s stock valued at $1,805,741,000 after buying an additional 228,920 shares during the period. Geode Capital Management LLC boosted its stake in shares of Eli Lilly And Co by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after purchasing an additional 830,689 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of Eli Lilly And Co by 8.1% in the 1st quarter. California Public Employees Retirement System now owns 3,162,898 shares of the company’s stock valued at $410,418,000 after purchasing an additional 238,198 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Eli Lilly And Co by 5.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 3,080,350 shares of the company’s stock valued at $399,706,000 after purchasing an additional 156,321 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Eli Lilly And Co by 1.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,396,949 shares of the company’s stock valued at $311,030,000 after purchasing an additional 41,525 shares during the last quarter. Institutional investors own 79.50% of the company’s stock.

LLY has been the topic of several recent research reports. Goldman Sachs Group initiated coverage on shares of Eli Lilly And Co in a research note on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research note on Tuesday, April 23rd. Barclays reaffirmed a “buy” rating and issued a $140.00 target price on shares of Eli Lilly And Co in a research note on Sunday, April 14th. Finally, ValuEngine lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $123.49.

Shares of NYSE:LLY traded up $1.91 during mid-day trading on Friday, reaching $112.42. The stock had a trading volume of 4,477,611 shares, compared to its average volume of 4,018,415. The company has a market cap of $107.29 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 1.95 and a beta of 0.19. The stock has a 50 day moving average of $111.04. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. Eli Lilly And Co has a twelve month low of $98.88 and a twelve month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. The business had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 58.65%. Eli Lilly And Co’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the company posted $1.48 EPS. On average, equities research analysts expect that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $0.645 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.29%. Eli Lilly And Co’s dividend payout ratio is 46.49%.

In other news, CFO Joshua L. Smiley purchased 426 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were acquired at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the transaction, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the sale, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.